New antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT07046923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called LY4175408, which is designed to seek out and attack cancer cells that have a specific marker (PTK7). The study includes 240 people with advanced lung, endometrial, or triple-negative breast cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and get an early look at whether the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LY4175408 (an antibody drug conjugate that targets PTK7 on tumor cells, given by IV infusion, sometimes with pembrolizumab, carboplatin, or cisplatin)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced lung, endometrial, or triple-negative breast cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial, so the drug may not be safe or effective. Side effects are unknown, and the study is small (240 people) with no guarantee of benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGTokyo, 135-8550, Japan
-
Centre Leon Berard
RECRUITINGLyon, 69373, France
-
Columbia University
RECRUITINGNew York, New York, 10032, United States
-
Community Health Network
RECRUITINGIndianapolis, Indiana, 46250, United States
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute
RECRUITINGOrlando, Florida, 32827, United States
-
Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34236, United States
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, 28041, Spain
-
Hospital Universitario Vall d'Hebron
RECRUITINGBarcelona, 08035, Spain
-
Institut Gustave Roussy
RECRUITINGVillejuif, 94805, France
-
John Theurer Cancer Center At Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
-
Kyoto University Hospital
RECRUITINGKyoto, 606-8507, Japan
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
National Cancer Center Hospital
RECRUITINGTokyo, 104-0045, Japan
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
-
Sarah Cannon Research Institute
RECRUITINGNashville, Tennessee, 37203, United States
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
-
Shanghai East Hospital, Tongji University
NOT_YET_RECRUITINGShanghai, 0200120, China
-
Stanford Medicine Cancer Center
RECRUITINGStanford, California, 94305, United States
-
The Ohio State University (OSU) Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
-
The University of Chicago Medical Center (UCMC)
RECRUITINGChicago, Illinois, 60637, United States
-
Tongji Hospital - Tongji Medical College of HUST
NOT_YET_RECRUITINGWuhan, 430030, China
-
Washington University
RECRUITINGSt Louis, Missouri, 63110, United States
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, 610041, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?